Efficacy and Safety of Everolimus in Elderly Patients with mRCC
نویسندگان
چکیده
1Department of Urology, Osaka Medical College, Takatsuki, 2Department of Urology, Osaka University, Graduate School of Medicine, Suita, 4Department of Urology, Kansai Medical University, Hirakata, 5Department of Urology, Kinki University School of Medicine, Osaka-Sayama, 6Chiba Cancer Center, Chiba, 8Department of Urology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, 9Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, 10Department of Urology, Yamagata University, Faculty of Medicine, Yamagata, 7Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Higashinari-ku, 3Department of Urology, Osaka City University, 11Sumitomo Hospital, 12Osaka Rosai Hospital, Osaka, Japan *For correspondence: [email protected] Abstract
منابع مشابه
Everolimus in metastatic renal cell carcinoma: preliminary experience from Chang Gung Memorial Hospital.
BACKGROUND Everolimus has been approved for second-line treatment of patients with metastatic renal cell carcinoma (mRCC) after failure of sorafenib or sunitinib. The purpose of this retrospective study was to assess the efficacy and safety of everolimus in Taiwanese patients with mRCC. METHODS Between March 2009 and August 2011, 24 mRCC patients treated with everolimus were analyzed. Prior t...
متن کاملClinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
INTRODUCTION Renal cell carcinoma (RCC) represents 2%-3% of all cancers in adults, and its pathogenesis is mainly related to altered cellular response to hypoxia. Lenvatinib, a novel multitarget tyrosine kinase inhibitor (TKI), represents a therapeutic option, in combination with mammalian target of rapamycin (mTOR) inhibitor everolimus, for the treatment of metastatic RCC (mRCC). AIM The obj...
متن کاملA national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey – NOTES study
Introduction The introduction of targeted therapies in renal cell carcinoma has significantly improved its prognosis and treatment outcomes in recent years. Such treatment options are targeted therapies of the vascular endothelial growth factor (VEGF) pathway and the mammalian target of the rapamycin pathway. With the use of tyrosine kinase inhibitors (TKIs) and mammalian target of the rapamyci...
متن کاملEfficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor
PURPOSE The purpose of this study is to assess the efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma (mRCC) for whom initial treatment with a vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) has failed. MATERIALS AND METHODS Eligible patients with mRCC (any histology) who had progressed on or were intolerant of VEGFr-TKI...
متن کاملCurrent and Future Treatment Options for Metastatic Renal Cell Carcinoma
Context: Metastatic renal cell carcinoma (mRCC) is associated with poor survival, and until recently, treatment options have been very limited. However, the advent of targeted therapies has radically improved the outlook for patients with mRCC. Objective: This review describes current treatment options for mRCC and summarizes the data on efficacy and safety of approved and newly emerging target...
متن کامل